- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
More ▼
Key statistics
On Thursday, Inhibikase Therapeutics Inc (IKT:NAQ) closed at 1.34, 69.62% above the 52 week low of 0.79 set on Oct 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.39 |
---|---|
High | 1.40 |
Low | 1.29 |
Bid | 1.29 |
Offer | 1.65 |
Previous close | 1.35 |
Average volume | 94.56k |
---|---|
Shares outstanding | 6.48m |
Free float | 5.58m |
P/E (TTM) | -- |
Market cap | 8.74m USD |
EPS (TTM) | -3.62 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼